First-line cisplatin with docetaxel or vinorelbine in patients with advanced non-small-cell lung cancer: A quality of life directed phase II randomized trial of Gruppo Oncologico Italia Meridionale

Lung Cancer

Volumn 69, Issue 2, 2010, Pages 218-224

  Gebbia, Vittorio ^a   Lorusso, Vito ^b   Galetta, Domenico ^c   Caruso M, Michele ^d   Palomba, Giuseppe ^e   Riccardi, Fernando ^f   Borsellino, Nicolò ^g   Carrozza, Francesco ^h   Leo, Silvana ^b   Ferra, Francesco ⁱ   Cinieri, Saverio ^j   Mancuso, Gianfranco ^a   Mancarella, Sergio ^k   Colucci, Giuseppe ^c  

^a UNIVERSITY OF PALERMO   (Italy)

^b VITO FAZZI HOSPITAL   (Italy)

^c Istituto Oncologico   (Italy)

^d Medical Oncology Unit   (Italy)

^e CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^f CARDARELLI HOSPITAL   (Italy)

^g Buccheri La Ferla Hospital   (Italy)

^h Ospedale A Cardarelli   (Italy)

ⁱ Ospedale S Vincenzo   (Italy)

^j Ospedale Perrino   (Italy)

^k Ospedale Civile   (Italy)

more..

Author keywords

Chemotherapy; Docetaxel; Non small cell lung cancer; Quality of life; Vinorelbine

Indexed keywords

CISPLATIN; DEXAMETHASONE; DOCETAXEL; ERLOTINIB; ERYTHROPOIETIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; NAVELBINE; ONDANSETRON; PEMETREXED;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; CANCER STAGING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HAIR LOSS; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROLOGIC DISEASE; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PATIENT ATTITUDE; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THROMBOCYTE; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; CLINICAL PROTOCOLS; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUTROPENIA; QUALITY OF LIFE; SURVIVAL ANALYSIS; TAXOIDS; VINBLASTINE;

EID: 77954143903     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.10.008     Document Type: Article

References (32)

1. Jemal A., Sieger R., Ward E., et al. Cancer statistics, 2007. CA Cancer J Clin 2007, 57:43-66.
2. NSCLC Meta-Analyses Collaborative Group Chemotherapy in addition to supportive care improves survival in advanced non-small-cell: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2006, 26:4617-4625.
3. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 14(355 (24)):2542-2550.
4. Pirker R., Szczesna A., von Pawel J., et al. A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2008, 26. [abstract 3].
5. Scagliotti G.V., Parikh P., von Pawel J., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26(July (21)):3543-3551.
6. Schiller J., Harrington D., Belani C., et al. A randomized phase III trial of four chemotherapy regimens in advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
7. Ettinger D.S., Akerley W., Bepler G., et al. Non-small-cell lung cancer. J Natl Compr Cancer Netw 2008, 6:228-269.
8. Johnson J.R., Williams G., Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 2003, 21:1404-1411.
9. Chassany O., Sagnier P., Marquis P., et al. Patient-reported outcomes: the example of health-related quality of life-a European guidance document for the improved integration of health-related quality of life assessment in the drug regulatory process. Drug Inform J 2002, 36:209-238.
10. Hollen P.J., Gralla R.J., Kris M.G., et al. Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the lung cancer symptom scale. Cancer 1994, 73:2087-2098.
11. Gotay C.C., Kawamoto C.T., Bottomley A., Efficace F. The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol 2008, 26:1355-1363.
12. Scagliotti G.V., De Marinis F., Rinaldi M., et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol 2002, 20:4285-4291.
13. Fossella F., Pereira J.R., von Pawel J., et al. Randomized, multinational, phase III study of docetaxel plus platinum versus vinorelbine plus platinum for advanced non-small-cell lung cancer: the TAX 326 Study Group. J Clin Oncol 2003, 21:3016-3024.
14. Martoni A., Marino A., Sperandi F., et al. Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer. Eur J Cancer 2005, 41:81-92.
15. Gebbia V., Galetta D., Lorusso V., et al. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine day 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale. Lung Cancer 2008, 61:369-377.
16. Gridelli C., Gallo C., Shepherd F.A., et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003, 21:1-11.
17. Winton T., Livingstone R., Johnson D., et al. Vinorelbine and cisplatin vs observation in resected non-small cell lung cancer. N Engl J Med 2005, 352:2589-2597.
18. Douillard J.Y., Rosell R., De Lena M., et al. Adjuvant vinorelbine plus cisplatin versus observation in completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association-ANITA): a randomized controlled trial. Lancet Oncol 2006, 7:719-727.
19. Therasse P., Arbuck S.G., Eisenhauer E.E., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-216.
20. Fleming T.R. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982, 38:143-151.
21. Cancer Therapy Evaluation Program Revised March 23, 1998. Common Toxicity Criteria, Version 2.0. DCTD, NCI, NIH, DHHS March 1998.
22. Hryniuk W.M., Goodyear M. The calculation of received dose intensity. J Clin Oncol 1990, 8:1935-1937.
23. Kaplan E.L., Meier P. Nonparamentric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481.
24. Harper P., Plunkett T., Khayat D. Quality trials and quality of life in non-small-cell lung cancer. J Clin Oncol 2003, 21:3007-3008.
25. American Society of Clinical Oncology: outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 1996, 14:671-679.
26. Gralla R.J., Thatcher N. Quality-of-life assessment in advanced lung cancer: consideration for evaluation in patients receiving chemotherapy. Lung Cancer 2004, 46(Suppl. 2):S41-47.
27. Stephens R. Quality of life issues in non-small cell lung cancer. Exp Rev Pharmacoeconom Outc Res 2004, 4:215-226.
28. Spiro S.G., Rudd R.M., Souhami R.L., et al. Chemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life. Thorax 2004, 59:828-836.
29. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol 2008, 26:4617-4625. NSCLC Meta-Analyses Collaborative Groups.
30. Dediu M. Should we discard vinorelbine plus cisplatin from the first-line therapy of advanced non-small-cell lung cancer ?. J Clin Oncol 2004, 22:1345-1347.
31. Tan E.H., Grodski T., Schneider C.P., et al. Global lung oncology branch trial 3 (GLOB-3): final results of a randomised multinational phase III study of oral and iv vinorelbine (NVB) plus cisplatin (CDDP) versus docetaxel (DXT) plus CDDP as first line treatment for advanced non small cell lung cancer (NSCLC). J Thor Oncol 2008, 2(Suppl. 4). [abs s451].
32. Douillard J.Y., Laporte S., Fossella F., et al. Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials. J Thor Oncol 2007, 2:939-946.